UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
Form 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended March 31, 2001.
[_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Commission File number 000-29173
Diversa Corporation
(Exact name of registrant as specified in its charter)
Delaware 22-3297375
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
4955 Directors Place, San Diego, California 92121
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code is (858) 526-5000
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. [X] Yes [_] No
The number of shares of the Registrant's Common Stock outstanding as of May 9,
2001 was 35,106,951.
DIVERSA CORPORATION
INDEX
Page No.
--------
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Condensed Balance Sheets as of March 31, 2001 (unaudited)
and December 31, 2000............................................... 3
Condensed Statements of Operations (unaudited) for the
three months ended March 31, 2001 and 2000.......................... 4
Condensed Statements of Cash Flows (unaudited) for the
three months ended March 31, 2001 and 2000.......................... 5
Notes to Condensed Financial Statements.............................. 6
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations................................. 8
Item 3. Quantitative and Qualitative Disclosures about Market Risk........... 13
PART II - OTHER INFORMATION
Item 1 Legal Proceedings.................................................... 14
Item 2 Change in Securities and Use of Proceeds............................. 14
Item 3 Defaults Upon Senior Securities...................................... 14
Item 4 Submission of Matters to a Vote of Securities Holders................ 14
Item 5 Other Information.................................................... 14
Item 6 Exhibits and Reports on Form 8-K..................................... 14
SIGNATURES................................................................... 15
2
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
DIVERSA CORPORATION
CONDENSED BALANCE SHEETS
(In thousands, except share and per share data)
ASSETS MARCH 31, DECEMBER 31,
2001 2000
----------- ------------
(unaudited) (Note)
Current assets:
Cash and cash equivalents.......................................... $ 64,501 $ 62,382
Short-term investments............................................. 139,622 148,874
Accounts receivable................................................ 1,992 587
Other current assets............................................... 5,674 5,849
---------- -----------
Total current assets............................................ 211,789 217,692
Property and equipment, net......................................... 17,455 14,903
Acquired technology rights, net..................................... 2,292 2,331
Other assets........................................................ 1,166 335
---------- -----------
Total assets........................................................ $ 232,702 $ 235,261
========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable................................................... $ 2,223 $ 2,002
Accrued liabilities................................................ 2,823 6,108
Deferred revenue................................................... 8,139 8,101
Current portion of capital lease obligations....................... 878 819
Current portion of notes payable................................... 1,881 1,439
---------- -----------
Total current liabilities....................................... 15,944 18,469
Capital lease obligations, less current portion..................... 2,459 2,688
Notes payable, less current portion................................. 6,760 5,494
Deposit from sublessee.............................................. --- 300
Long-term deferred revenue.......................................... 12,529 14,236
Stockholders' equity:
Common stock-$0.001 par value; 65,000,000 shares authorized,
35,106,045 and 34,890,806 shares issued and outstanding at
March 31, 2001 and December 31, 2000, respectively................ 35 35
Additional paid-in capital......................................... 261,999 260,929
Deferred compensation.............................................. (1,682) (2,137)
Accumulated deficit................................................ (67,079) (65,725)
Accumulated other comprehensive income............................. 1,737 972
---------- -----------
Total stockholders' equity..................................... 195,010 194,074
---------- -----------
Total liabilities and stockholders' equity..................... $ 232,702 $ 235,261
========== ===========
Note: The balance sheet at December 31, 2000 has been derived from the audited
financial statements at that date but does not include all of the information
and footnotes required by generally accepted accounting principles for complete
financial statements.
See accompanying notes to condensed financial statements.
3
DIVERSA CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
THREE MONTHS ENDED
MARCH 31,
-----------------------
2001 2000
---------- ----------
Revenue:
Collaborative............................................................ $ 7,881 $ 4,064
Grant and product........................................................ 334 342
------- -------
Total revenue............................................................. 8,215 4,406
------- -------
Operating costs and expenses:
Research and development................................................. 9,868 4,574
Selling, general and administrative...................................... 2,122 1,303
Non-cash, stock-based compensation charges............................... 747 5,555
------- -------
Total operating costs and expenses........................................ 12,737 11,432
------- -------
Loss from operations...................................................... (4,522) (7,026)
Interest income, net...................................................... 3,303 1,412
Other income (expense), net............................................... (135) 2
------- -------
Loss before income taxes.................................................. (1,354) (5,612)
Provision for income taxes................................................ --- 75
------- -------
Net loss before preferred dividends....................................... (1,354) (5,687)
Dividends on preferred stock.............................................. --- 310
------- -------
Net loss applicable to common stockholders................................ $(1,354) $(5,997)
======= =======
Net loss per share, basic and diluted..................................... $ (0.04) $ (0.32)
Weighted average shares used in calculating basic and diluted
net loss per share....................................................... 34,963 18,979
See accompanying notes to condensed financial statements.
4
DIVERSA CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
THREE MONTHS ENDED
MARCH 31,
----------------------------
2001 2000
------------ ------------
Operating activities:
Net loss applicable to common stockholders...................................... $ (1,354) $ (5,997)
Adjustments to reconcile net loss to net cash provided by (used in) operating
activities:
Depreciation and amortization................................................ 1,110 484
Dividends to Series A, B and D preferred stockholders........................ --- 310
Non-cash, stock based compensation charges................................... 747 5,555
Change in operating assets and liabilities:
Accounts receivable........................................................ (1,405) 14,403
Other assets............................................................... (656) (560)
Accounts payable and accrued expenses...................................... (3,064) 781
Deferred revenue........................................................... (1,669) (1,171)
---------- ----------
Net cash provided by (used in) operating activities.......................... (6,291) 13,805
---------- ----------
Investing activities:
Purchases of short-term investments............................................. (32,229) (34,834)
Sales and maturities of short-term investments.................................. 42,246) 1,107
Purchases of property and equipment............................................. (3,623) (2,248)
Other........................................................................... (300 (28)
---------- ----------
Net cash provided by (used in) investing activities.......................... 6,094 (36,003)
---------- ----------
Financing activities:
Net proceeds from sale of common stock.......................................... 778 185,388
Principal payments on capital leases............................................ (170) (132)
Principal payments on notes payable............................................. (401) ---
Advances under capital lease obligations........................................ --- 819
Proceeds from notes payable..................................................... 2,109 ---
Repayment of notes receivable from stockholders................................. --- 35
---------- ----------
Net cash provided by financing activities.................................... 2,316 186,110
---------- ----------
Net increase in cash and cash equivalents......................................... 2,119 163,912
Cash and cash equivalents at beginning of period.................................. 62,382 2,553
---------- ----------
Cash and cash equivalents at end of period........................................ $ 64,501 $ 166,465
========== ==========
Supplemental disclosure of cash flow information:
Interest paid................................................................ $ 249 $ 137
========== ==========
See accompanying notes to condensed financial statements.
5
DIVERSA CORPORATION
NOTES TO CONDENSED FINANCIAL STATEMENTS
(Unaudited)
1. Organization and Business
Diversa Corporation (the "Company") was incorporated under the laws of the State
of Delaware on December 21, 1992 and received initial funding to commence its
operations in May 1994. The Company is developing and applying its proprietary
technologies to discover and evolve novel genes and gene pathways from diverse
environmental sources. The Company is utilizing its fully integrated approach to
develop novel enzymes and other biologically active compounds, such as small
molecule drugs. The Company's proprietary evolution technologies facilitate the
optimization of genes found in nature to enable product solutions in the
pharmaceutical, agricultural, chemical, and industrial markets.
2. Basis of Presentation
The accompanying unaudited financial statements have been prepared by the
Company in accordance with accounting principles generally accepted in the
United States for interim financial information. Accordingly, they do not
include all the information and footnotes required by accounting principles
generally accepted in the United States for complete financial statements. In
the opinion of management, all adjustments, consisting of normal recurring
accruals, which are necessary for a fair statement of the results of the interim
periods presented, have been included. The results of operations for the interim
period are not necessarily indicative of results to be expected for any other
interim period or for the year as a whole. These unaudited condensed financial
statements and footnotes thereto should be read in conjunction with the audited
financial statements and footnotes thereto contained in the Company's Annual
Report on Form 10-K for the year ended December 31, 2000.
The preparation of financial statements in accordance with accounting principles
generally accepted in the United States requires management to make estimates
and assumptions that affect amounts reported in the condensed financial
statements and related footnotes. Changes in the estimates may affect amounts
reported in future periods.
Certain reclassifications of prior year balances have been made to conform to
the current format.
3. Strategic Alliance
In January 2001, the Company signed a drug discovery, development, and licensing
agreement with IntraBiotics Pharmaceuticals, Inc. Under the terms of the
agreement, the companies will work together to identify and develop novel small
molecule drugs derived from the Company's recombinant natural product libraries
that demonstrate antibacterial or antifungal properties. The Company will
receive technology access fees, research support, and success-based milestone
payments for each drug developed as well as royalties on any products
commercialized under the agreement.
6
4. Computation of Net Loss Per Share
In accordance with Statement of Financial Accounting Standards No. 128,
"Earnings Per Share" ("SFAS No. 128"), basic and diluted net loss per common
share has been computed using the weighted-average number of shares of common
stock outstanding during the period, less shares subject to repurchase. Pro
forma net loss per common share has been computed for the quarter ended March
31, 2000 as described above, and also gives effect to the assumed conversion of
preferred stock (using the "as if converted" method), which automatically
converted to common stock upon completion of the Company's initial public
offering in February 2000, at the original dates of issuance.
The following table presents the calculation of basic, diluted, and pro forma
basic and diluted net loss per common share:
(in thousands, except per share data)
Three Months Ended March 31,
--------------------------------
2001 2000
--------------------------------
Net loss applicable to common stockholders................................ $ (1,354) $ (5,997)
Historical net loss per common share, basic and diluted................... $ (0.04) $ (0.32)
Weighted average shares used in computing basic and diluted net loss per
common share............................................................. 34,963 18,979
Pro forma net loss per common share, basic and diluted.................... $ --- $ (0.20)
Weighted average shares used in computing pro forma basic and diluted net
loss per common share.................................................... --- 29,976
The Company has excluded all outstanding stock options and warrants from the
calculation of diluted net loss per common share because all such securities are
antidilutive for all applicable periods presented.
7
5. Recently Issued Accounting Standards
In June 1998, the Financial Accounting Standards Board issued SFAS No. 133,
Accounting for Derivative Instruments and Hedging Activities, which became
effective January 1, 2001. This statement establishes accounting and reporting
standards requiring that every derivative instrument, including derivative
instruments embedded in other contracts, be recorded in the balance sheet as
either an asset or liability measured at its fair value. The statement also
requires that changes in the derivative's fair value be recognized in earnings
unless specific hedge accounting criteria are met. The adoption of SFAS No. 133
did not have a material effect on the financial statements, since the Company
currently does not engage in hedging activities or invest in derivative
instruments.
6. Comprehensive Income
SFAS No. 130, "Reporting Comprehensive Income" ("SFAS 130"), requires reporting
and displaying comprehensive income (loss) and its components which, for the
Company, includes net loss and unrealized gains and losses on investments. In
accordance with SFAS 130, the accumulated balance of other comprehensive income
is disclosed as a separate component of stockholders' equity.
For the three months ended March 31, 2001 and 2000, respectively, comprehensive
loss consisted of:
(in thousands)
2001 2000
---------- ----------
Net loss before preferred dividends $ (1,354) $ (5,687)
Other comprehensive gain (loss):
Unrealized gain (loss) on investments 765 (126)
---------- ----------
Comprehensive loss $ (589) $ (5,813)
========== ==========
Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations
The statements in this quarterly report that are not descriptions of historical
facts may be forward-looking statements that are subject to risks and
uncertainties. These include statements related to investments in our core
technologies, the discovery, development, and/or optimization of novel genes,
enzymes, and other biologically active compounds, the development and
commercialization of products and product candidates, the benefits to be derived
from our current and future strategic alliances, and our estimates regarding
future revenue, profitability, and capital requirements, all of which are
prospective. Such statements are only predictions and reflect our expectations
and assumptions as of the date of this report based on currently available
operating, financial, and competitive information. The actual events or results
may differ materially from those projected in such forward-looking statements.
Actual results could differ materially from those currently anticipated due to a
number of factors, including those identified
8
below and in our other publicly available documents. These forward-looking
statements speak only as of the date of this report. We expressly disclaim any
intent or obligation to update any of these forward-looking statements after the
filing of this quarterly report to reflect actual results, changes in our
expectations, or otherwise.
The following information should be read in conjunction with the condensed
financial statements and the notes thereto included in Item 1 of this quarterly
report. We also urge readers to review and consider our disclosures describing
various factors that affect our business in our Annual Report on Form 10-K for
the year ended December 31, 2000, including the disclosures under the captions
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" and "Risk Factors Related to Our Business," as well as the audited
financial statements and notes thereto contained in such report.
Overview
We were incorporated in December 1992 and began operations in May 1994. We are
applying proprietary technologies to discover and evolve novel genes and gene
pathways from diverse environmental sources. We use our fully integrated
approach to develop novel enzymes and other biologically active compounds, such
as small molecule drugs. Our proprietary evolution technologies facilitate the
optimization of genes found in nature to enable product solutions for the
pharmaceutical, agricultural, chemical, and industrial markets. To date, we have
generated revenue from research collaborations, government grants, and enzyme
product sales and royalties. Our strategic partners include Aventis Animal
Nutrition S.A., Celanese Ltd., Celera Genomics, Finnfeeds International Ltd (a
unit of Danisco Cultor), The Dow Chemical Company, GlaxoSmithKline plc,
IntraBiotics Pharmaceuticals, Inc., Invitrogen Corporation, and Syngenta. We
have also formed joint ventures with The Dow Chemical Company and with Syngenta
Seeds AG. Our current government grants are from the National Science
Foundation, the National Institute of General Medical Sciences, the National
Cancer Institute, and the National Institute of Environmental Health Sciences.
Our product related revenues to date are comprised of research kits, Pyrolase
160 enzyme and Pyrolase 200 enzyme, enzymes used in oil and gas recovery, and
royalties from sales of ThermalAce(TM), a DNA polymerase licensed to Invitrogen
Corporation for molecular biology research applications.
We have dedicated substantial resources to the development of our proprietary
technologies, which include capabilities for sample collection from the world's
microbial populations, generation of environmental gene libraries, screening of
these libraries using ultra high-throughput methods capable of analyzing more
than one billion genes per day, and optimization based on our gene evolution
technologies.
Our revenue has increased significantly since our inception, and for the quarter
ended March 31, 2001, revenue grew 86% compared to the quarter ended March 31,
2000. This increase was primarily attributable to the addition of new strategic
alliances, which included research funding and technology access and development
fees. Strategic alliance revenues are earned and recognized on a percentage of
completion basis as research costs are incurred in accordance with the
provisions of each strategic alliance agreement. Fees received to initiate
research projects are
9
deferred and recognized over the project period. Fees received for exclusivity
in a field are deferred and recognized over the period of the exclusivity.
Milestone payments are recognized when earned, as evidenced by written
acknowledgement from the collaborator, provided that (i) the milestone event is
substantive and its achievement was not reasonably assured at the inception of
the agreement and (ii) our performance obligations after the milestone
achievement will continue to be funded by the collaborator at a level comparable
to the level before the milestone achievement. Our strategic partners often pay
us before we recognize the revenue, and these payments are deferred until
earned. As of March 31, 2001, we had current and long-term deferred revenue
totaling $20.7 million.
We have incurred substantial operating losses since our inception. As of March
31, 2001, our accumulated deficit was $67.1 million. We expect to incur
additional operating losses over the next few years as we continue to develop
our technologies and fund internal product research and development.
Results of Operations
Quarters ended March 31, 2001 and March 31, 2000
Revenue
Our revenue increased $3.8 million to $8.2 million for the quarter ended March
31, 2001 from $4.4 million for the same period in 2000. The increase in
revenues resulted from a number of strategic collaboration agreements signed in
2000 and early 2001. The two most significant components of first quarter 2001
revenues are related to Zymetrics, the Company's agricultural products contract
joint venture with Syngenta Seeds AG, and Innovase LLC, the Company's 50/50
industrial enzyme joint venture with The Dow Chemical Company. Revenue from
collaborations accounted for 96% of total revenue for the quarter ended March
31, 2001 and for 92% of total revenue for the quarter ended March 31, 2000.
Research and Development Expenses
Our research and development expenses increased $5.3 million to $9.9 million for
the quarter ended March 31, 2001 from $4.6 million for the same period in 2000.
This increase was primarily attributable to the expansion of collaborative
research activities, as well as the continued investment in several key internal
programs and technologies. We expect that our research and development expenses
will continue to increase substantially to support our collaborative research
programs, internal product research and development, and technology development.
Selling, General and Administrative Expenses
Our selling, general and administrative expenses increased $0.8 million to $2.1
million for the quarter ended March 31, 2001 from $1.3 million for the same
period in 2000. This increase was primarily attributable to the expansion of
administrative infrastructure to support our growth and
10
requirements as a public company. We expect that our selling, general and
administrative expenses will continue to increase to support our anticipated
growth.
Non-Cash, Stock-Based Compensation Charges
Deferred compensation for options granted to employees has been determined as
the difference between the exercise price and the fair value of our common
stock, as estimated by us for financial reporting purposes, on the date options
were granted. Deferred compensation for options granted to consultants has been
determined in accordance with the Statement of Financial Accounting Standards
No. 123 as the fair value of the equity instruments issued, and is periodically
remeasured as the underlying options vest in accordance with EITF 96-18.
For the quarter ended March 31, 2001, we recorded amortization of deferred
compensation of approximately $0.5 million compared to $1.1 million for the
quarter ended March 31, 2000. We also recorded aggregate non-cash compensation
charges of $0.3 million in the quarter ended March 31, 2001 compared to $4.4
million in the quarter ended March 31, 2000, which includes $4.1 million in
conjunction with the acceleration of vesting for stock options held by
employees.
Interest Income, net
Interest income increased to $3.6 million for the quarter ended March 31, 2001
from $1.5 million for the same period in 2000 due to higher average cash
balances following the Company's initial public offering in February 2000.
Interest expense increased $0.2 million to $0.3 million for the quarter ended
March 31, 2001, primarily due to interest on borrowings under our equipment
financing line of credit.
Provision for Income Taxes
During the quarter ended March 31, 2001, we incurred a net operating loss and,
accordingly, did not record a provision for income taxes. We recorded a
provision for income taxes of $75,000 for the quarter ended March 31, 2000 based
on our estimated tax liability for 2000, assuming we were subject to alternative
minimum taxes under which net operating loss carryforwards were available to
offset 90% of our tax liability.
Dividends
From December 21, 1999 until the date of the consummation of the first sale of
common stock in an initial public offering, our Series A, B and D preferred
stockholders were entitled to a 5% dividend per annum. We recorded dividends of
$66,000 at the end of December 31, 1999, and during the first quarter of 2000,
we recorded additional dividends of $310,000. These dividends were settled
through the issuance of shares of common stock valued at the initial public
offering price on February 14, 2000.
11
Liquidity and Capital Resources
Since inception, we have financed our business primarily through the sale of
common and preferred stock and over $56 million of funding received from
collaborators. As of March 31, 2001, we had cash, cash equivalents, and short-
term investments of approximately $204.1 million. Our funds are currently
invested in U.S. Treasury and government agency obligations and investment-grade
corporate securities. During the first quarter of 2001, we funded an additional
$2.1 million of equipment purchases through our equipment financing line of
credit agreement. The credit agreement expired on March 31, 2001. Through the
expiration date, we financed a total of $9.5 million of equipment purchases. As
of March 31, 2001, we had an aggregate of $8.7 million of notes payable due
under the credit agreement with various maturity dates through February 2005. We
anticipate funding our remaining capital requirements in 2001 under similar
financing agreements.
We relocated to our new executive offices and research and development facility
in November 2000. As part of the move, we constructed a pilot manufacturing
plant to be used for process development activities. Our costs for property and
equipment relating to the pilot manufacturing plant were approximately $3.6
million, all of which we funded through working capital and our equipment
financing line of credit. We entered into a lease agreement for an additional
research and development facility to be built to the Company's specifications.
The facility is expected to be completed in the first quarter of 2002. We plan
to incur costs for property and equipment related to the new facility beginning
in the fourth quarter of 2001. Additionally, we have commitments to further fund
$0.6 million in enhancements to our SciLect(TM) data management and analysis
system through the second quarter of 2001.
Our operating activities used cash of $6.3 million for the quarter ended March
31, 2001. Our cash used in operating activities consisted primarily of payment
of accrued liabilities and cash used to fund operations.
Our investing activities provided cash of $6.1 million in the quarter ended
March 31, 2001. Our investing activities consisted primarily of sales and
maturities of short-term investments, offset by purchases of short-term
investments and of property and equipment.
Our financing activities provided cash of $2.3 million in the quarter ended
March 31, 2001. Our financing activities consisted primarily of proceeds
received from the issuance of shares under our Employee Stock Purchase Plan,
proceeds from the exercise of stock options and warrants and proceeds received
under our equipment financing line of credit, partially offset by principal
payments made against our line of credit and capital leases.
We expect that our current cash and cash equivalents, short-term investments,
and funding from existing strategic alliances and grants will be sufficient to
fund our operations for the foreseeable future. This estimate is a forward-
looking statement that involves risks and uncertainties. Our future capital
requirements and the adequacy of our available funds will depend on many
factors, including scientific progress in our research and development programs,
the magnitude of those programs, our ability to maintain our strategic alliances
and establish new strategic alliance relationships, our ability, alone or with
our strategic partners, to commercialize products successfully and competing
technological and market developments. Therefore, it is possible that we may
seek additional financing in the future, whether through private or public
equity offerings, debt financings, or strategic alliances, which may not be
available on terms favorable to
12
us, if at all. In addition, if we enter into financing arrangements in the
future, such arrangements could dilute some stockholders' ownership interests
and adversely affect their rights.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Our exposure to market risk for changes in interest rates relates primarily to
the increase or decrease in the amount of interest income we can earn on our
investment portfolio and on the increase or decrease in the amount of interest
expense we must pay with respect to our various outstanding debt instruments.
Our risk associated with fluctuating interest expense is limited, however, to
our capital lease obligations and notes payable, the interest rates under which
are closely tied to market rates, and our investments in interest rate sensitive
financial instruments. Under our current policies, we do not use interest rate
derivative instruments to manage exposure to interest rate changes. We ensure
the safety and preservation of our invested principal funds by limiting default
risk, market risk, and reinvestment risk. We mitigate default risk by investing
in short-term investment grade securities. A hypothetical 100 basis point
adverse move in interest rates along the entire interest rate yield curve would
decrease the fair value of our interest sensitive financial instruments at March
31, 2001 and December 31, 2000 by $1.4 million and $1.3 million, respectively.
Declines in interest rates over time will reduce our interest income, while
increases in interest rates over time will increase our interest expense.
13
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
None
Item 2. Change in Securities and Use of Proceeds
A Registration Statement on Form S-1 (File No. 333-92853) relating to the
initial public offering of our common stock was declared effective by the
Securities and Exchange Commission on February 11, 2000. Upon completion of our
initial public offering, we received net proceeds of $184.7 million after
expenses. None of the proceeds from our initial public offering were used to
pay expenses of, or make payments to, our directors, officers, or affiliates or
10% owners of any class of our equity securities. From the time of receipt
through March 31, 2001, we have continued to invest the net proceeds from the
offering in cash equivalents and short-term investments.
Item 3. Defaults Upon Senior Securities
None
Item 4. Submission of Matters to a Vote of Securities Holders
None
Item 5. Other Information
None
Item 6. Exhibits and Reports on Form 8-K
(a) The following exhibits are filed as part of this report:
EXHIBIT
NUMBER DESCRIPTION OF DOCUMENT
- --------------------------------------------------------------------------------
10.44+ Drug Discovery, Development, and License Agreement between the Company
and IntraBiotics Pharmaceuticals, Inc. dated January 6, 2001.
(b) Reports on Form 8-K
None
____________
+ Confidential treatment will be requested with respect to portions of
this exhibit. Omitted portions will be filed separately with the
Securities and Exchange Commission.
14
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DIVERSA CORPORATION
Date: May 15, 2001 /s/ Karin Eastham
---------------------------------------------
Karin Eastham
Senior Vice President, Finance,
Chief Financial Officer and Secretary
(Principal Financial and Accounting Officer)
15
EXHIBIT INDEX
TO
FORM 10-Q
DIVERSA CORPORATION
EXHIBIT
NUMBER DESCRIPTION OF DOCUMENT
- --------------------------------------------------------------------------------
10.44+ Drug Discovery, Development, and License Agreement between the Company
and IntraBiotics Pharmaceuticals, Inc. dated January 6, 2001.
___________
+ Confidential treatment will be requested with respect to portions of
this exhibit. Omitted portions will be filed separately with the
Securities and Exchange Commission.
16